ACASTI PHARMA INC (ACST) Forecast, Price Target & Analyst Ratings
NASDAQ:ACST • CA00430K8656
3.37 USD
-0.03 (-0.88%)
At close: Oct 25, 2024
3.38 USD
+0.01 (+0.3%)
After Hours: 10/25/2024, 8:22:28 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ACASTI PHARMA INC (ACST).
Forecast Snapshot
Consensus Price Target
$8.16
+ 142.14% Upside
Next Earnings Forecast
Release DateNov 11, 2024
PeriodQ2 / 2025
EPS Estimate-$0.64
Revenue Estimate
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$8.16
Upside
+ 142.14%
From current price of $3.37 to mean target of $8.16, Based on 7 analyst forecasts
Low
$8.08
Median
$8.16
High
$8.40
Price Target Revisions
1 Month
33.33%
3 Months
33.33%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for ACST. The average price target is 8.16 USD. This implies a price increase of 142.14% is expected in the next year compared to the current price of 3.37.
The average price target has been revised upward by 33.33% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
ACST was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about ACST.
In the previous month the buy percentage consensus was at a similar level.
ACST was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-09-26 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-09-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-07 | Craig-Hallum | Initiate | Buy |
| 2023-02-15 | EF Hutton | Reiterate | Buy |
| 2022-12-19 | EF Hutton | Initiate | Buy |
| 2022-12-15 | HC Wainwright & Co. | Initiate | Buy |
| 2021-12-22 | Oppenheimer | Initiate | Outperform |
| 2021-12-21 | Oppenheimer | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateNov 11, 2024
PeriodQ2 / 2025
EPS Estimate-$0.64
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q-238.41%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
-50.72%
Next Earnings Summary
ACST is expected to report earnings on 11/11/2024. The consensus EPS estimate for the next earnings is -0.64 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 200K | -100.00% | 1.239M | 39.743M 3,107.67% | 72.783M 83.13% | 101.21M 39.06% | 118.83M 17.41% | ||||||
| EBITDA YoY % growth | -31.34M -136.17% | -22.12M 29.42% | -9.8M 55.70% | N/A -56.53% | N/A -18.19% | N/A 37.36% | -23.903M -110.48% | -26.838M -12.28% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -33.67M -119.35% | -24.44M 27.41% | -10.72M 56.14% | -17.238M -43.10% | -20.706M -18.97% | -16.61M 37.72% | -27.257M -139.79% | -26.423M 3.06% | -10.098M 61.78% | 8.564M 184.81% | 33.365M 289.60% | 47.922M 43.63% | |
| Operating Margin | N/A | N/A | -5,360.00% | N/A | N/A | N/A | N/A | -2,132.59% | -25.41% | 11.77% | 32.97% | 40.33% | |
| EPS YoY % growth | -9.12 7.63% | N/A -240.89% | N/A 80.95% | -0.86 85.53% | -2.69 -214.29% | -1.98 26.59% | -2.19 -11.02% | -1.78 19.11% | -0.16 90.82% | 0.61 474.72% | 1.56 155.09% | 2.15 37.91% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.64 -238.41% | -0.43 -42.68% | -0.33 -83.49% | -0.29 21.89% | -0.33 48.63% | -0.40 6.45% | -0.39 -16.67% |
| Revenue Q2Q % growth | 1.239M | ||||||
| EBITDA Q2Q % growth | -6.709M -225.70% | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.989M -237.63% | -6.193M -103.51% | -6.193M -89.79% | -5.505M -10.92% | -6.193M 11.39% | -7.569M -22.22% | -7.156M -15.56% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.24%
EPS Next 5 Year
22.76%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ACASTI PHARMA INC / ACST Forecast FAQ
Can you provide the average price target for ACASTI PHARMA INC stock?
7 analysts have analysed ACST and the average price target is 8.16 USD. This implies a price increase of 142.14% is expected in the next year compared to the current price of 3.37.
Can you provide the upcoming earnings date for ACASTI PHARMA INC?
ACASTI PHARMA INC (ACST) will report earnings on 2024-11-11, before the market open.
Can you provide the consensus estimates for ACASTI PHARMA INC next earnings?
The consensus EPS estimate for the next earnings of ACASTI PHARMA INC (ACST) is -0.64 USD and the consensus revenue estimate is 0 USD.